Democratize Private Credit Access With the PCR ETF

Private credit (PC) is a corner of the capital markets that is rapidly crossing over from institutional portfolios into wealth management channels. PC offers individual investors unprecedented access to middle-market yield, but accessing these institutional returns often comes with significant liquidity, fee, and structural trade-offs. This is where the Simplify VettaFi Private Credit Strategy ETF (PCR) democratizes accessibility for retail investors.Key Takeaways: PCR democratizes access to middle-market yields by bridging institutional private credit returns with public market liquidity. By investing in publicly traded Business Development Companies (BDCs) and Closed-End Funds (CEFs), PCR circumvents multi-year lockups, illiquidity gating, and complex Schedule K-1 tax filings while tracking the VettaFi Private Credit Index. The fund combines a high monthly distribution rate (11.6% as of August 31, 2026) with an active credit hedge strategy using total return swaps across quality and junk equities to cushion downside volatility during credit stress. See More: Get Attractive Yield in Private Credit Within an ETF WrapperExpansion of Private CreditPC is no longer a niche institutional asset class, but now a massive pillar of global finance. According to a report by the CFA Institute Research & Policy Center, global private credit assets under management surged tenfold from approximately $250 billion in 2010 to more than $2.6 trillion by mid-2025. As bank direct lending contracted following the global financial crisis, private credit stepped in to fill this middle-market financing void. Now, industry experts estimate that within the next decade, up to one-third of all professionally managed global assets could reside in private markets. However, this rapid expansion into retail and semi-retail channels brings distinct operational challenges. More specifically, the CFA Institute highlighted significant market risks inherent in traditional private credit vehicles. This includes severe liquidity mismatches, valuation opacity from model-based pricing, and restrictive lock-up periods. Individual investors navigating illiquid feeder funds or non-traded business development companies (BDCs) often face redemption gating, withdrawal restrictions, high fee structures, and complex K-1 tax reporting.Bridging the Institutional Gap With PCRGiven all the aforementioned issues, PCR presents a compelling solution. The fund specifically bridges the gap between private credit yields and public market accessibility. It seeks income and capital appreciation by focusing on publicly traded BDCs and closed-end funds (CEFs) that directly finance the private credit sector. This liquid structure provides retail investors direct exposure to middle-market debt while eliminating the multi-year lock-ups, limited redemptions, and administrative burdens typical of private direct-lending funds. To mitigate the market risks outlined in the CFA Institute report, PCR tracks the VettaFi Private Credit Index (the “Index”). This index selects higher-yielding, lower-volatility securities. Furthermore, PCR incorporates an active credit hedge strategy that utilizes total return swaps across equities to cushion downside volatility during credit stress. Key highlights of PCR: High Monthly Income: PCR features a 11.6% distribution rate (as of August 31, 2026) paid on a monthly schedule. Operational Efficiency: Delivers private credit exposure through a standard 1099 tax structure, avoiding complex Schedule K-1s. Liquid Execution: Trades daily on open exchanges, resolving the traditional liquidity mismatch and gating risks associated with illiquid private funds. As private credit continues its expansion into wealth management channels, PCR offers a disciplined, risk-managed vehicle for capturing institutional-grade yields with the inherent benefits of an ETF investment vehicle. For more news, information, and analysis, visit the Institutional Income Strategies Content Hub. vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.